HSPB3 and cancer: Moreover, flow cytometry confirmed an enhance in apoptosis rate in advanced tumor grade cell line TCCSUP, when chemotherapy agent DXR, was combined with the silencing of HSPB2 and HSPB3. Supportively, HSPB2 was found in previous studies to possess an anti-apoptotic role [49], and it is well established that deficiency in apoptotic pathways is a hallmark of many cancer types [58]; thus, therapeutic strategies that would target the apoptotic pathways could possibly constitute an effective therapeutic approach [59].